136 related articles for article (PubMed ID: 37499067)
1. Retrospective analysis of the uptake of active surveillance for low-risk prostate cancer in Zurich, Switzerland.
Poyet C; Scherer TP; Kunz M; Wanner M; Korol D; Rizzi G; Kaufmann B; Rohrmann S; Hermanns T
Swiss Med Wkly; 2023 Jul; 153():40103. PubMed ID: 37499067
[TBL] [Abstract][Full Text] [Related]
2. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry.
Weerakoon M; Papa N; Lawrentschuk N; Evans S; Millar J; Frydenberg M; Bolton D; Murphy DG
BJU Int; 2015 Apr; 115 Suppl 5():50-6. PubMed ID: 25601201
[TBL] [Abstract][Full Text] [Related]
3. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
4. Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US.
Cooperberg MR; Meeks W; Fang R; Gaylis FD; Catalona WJ; Makarov DV
JAMA Netw Open; 2023 Mar; 6(3):e231439. PubMed ID: 36862409
[TBL] [Abstract][Full Text] [Related]
5. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
6. Validation of active surveillance criteria for pathologically insignificant prostate cancer in Asian men.
Yamada Y; Sakamoto S; Sazuka T; Goto Y; Kawamura K; Imamoto T; Nihei N; Suzuki H; Akakura K; Ichikawa T
Int J Urol; 2016 Jan; 23(1):49-54. PubMed ID: 26450768
[TBL] [Abstract][Full Text] [Related]
7. Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer.
Olsson H; Nordström T; Clements M; Grönberg H; Lantz AW; Eklund M
Eur Urol Oncol; 2020 Oct; 3(5):640-647. PubMed ID: 31235395
[TBL] [Abstract][Full Text] [Related]
8. Population-Based Assessment of Determining Treatments for Prostate Cancer.
Chamie K; Williams SB; Hu JC
JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305
[TBL] [Abstract][Full Text] [Related]
9. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
11. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
Shah S; Beckmann K; Van Hemelrijck M; Challacombe B; Popert R; Dasgupta P; Rusere J; Zisengwe G; Elhage O; Santaolalla A
BMC Cancer; 2021 May; 21(1):573. PubMed ID: 34011308
[TBL] [Abstract][Full Text] [Related]
12. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
13. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance for prostate cancer.
Romero-Otero J; García-Gómez B; Duarte-Ojeda JM; Rodríguez-Antolín A; Vilaseca A; Carlsson SV; Touijer KA
Int J Urol; 2016 Mar; 23(3):211-8. PubMed ID: 26621054
[TBL] [Abstract][Full Text] [Related]
15. Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study.
Meunier ME; Eyraud R; Sénéchal C; Gourtaud G; Roux V; Lanchon C; Brureau L; Blanchet P
J Urol; 2017 May; 197(5):1229-1236. PubMed ID: 27993665
[TBL] [Abstract][Full Text] [Related]
16. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
[TBL] [Abstract][Full Text] [Related]
17. Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
Botejue M; Abbott D; Danella J; Fonshell C; Ginzburg S; Guzzo TJ; Lanchoney T; Marlowe B; Raman JD; Smaldone M; Tomaszewski JJ; Trabulsi EJ; Uzzo RG; Reese AC
J Urol; 2019 May; 201(5):929-936. PubMed ID: 30720692
[TBL] [Abstract][Full Text] [Related]
18. Factors Influencing Selection of Active Surveillance for Localized Prostate Cancer.
Liu J; Womble PR; Merdan S; Miller DC; Montie JE; Denton BT;
Urology; 2015 Nov; 86(5):901-5. PubMed ID: 26358397
[TBL] [Abstract][Full Text] [Related]
19. Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
Detsky JS; Ghiam AF; Mamedov A; Commisso K; Commisso A; Zhang L; Liu S; Klotz L; Loblaw A; Vesprini D
J Urol; 2020 Nov; 204(5):934-940. PubMed ID: 32330406
[TBL] [Abstract][Full Text] [Related]
20. Variation in Guideline Concordant Active Surveillance Followup in Diverse Urology Practices.
Luckenbaugh AN; Auffenberg GB; Hawken SR; Dhir A; Linsell S; Kaul S; Miller DC;
J Urol; 2017 Mar; 197(3 Pt 1):621-626. PubMed ID: 27663459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]